The Billion Dollar Blindspot: Who It's For and Who Sponsors It

Covers: Institutional investment intelligence, venture funding, biotech M&A, and clinical development trends across women's healthcare.
For: Healthcare investors, biotech founders, venture capitalists, and pharmaceutical business development executives.
Best for: Investors and healthcare leaders looking to deploy capital in women's health and biotech.
Skip if: General consumers looking for personal wellness, fitness, or individual medical advice.

Start with

What Ferring’s $1.38 billion Gameto deal tells us about fertility investing: Analyzes valuation, deal terms, and market dynamics in biotech fertility acquisitions.
Women’s Health Funding: OMass, Allara and a $100M Stillbirth Initiative: Breaks down recent venture capital funding rounds and commercialization trends in specialized healthcare.
The Precision Premium: A New Lens on Women’s Health Investing: Explains market opportunities and regulatory considerations when investing in female-specific drug development.

Summarised by AI from 12 recent issues. Audience size is not included. Prices are not included. Report a mistake.